ABMC Phone: 800-227-1243
518-758-8158

ABMC Reports Second Quarter 2012 Results

KINDERHOOK, N.Y. - August 14, 2012 - American Bio Medica Corporation (ABMC.PK) today announced financial results for the three and six months ended June 30, 2012.

Net sales for the second quarter of 2012 were $2,462,000, compared to $2,486,000 for the second quarter of 2011, representing a decrease of $24,000, or less than 1%. For the six months ended June 30, 2012, net sales were $4,758,000, compared to $4,533,000 for the six months ended June 30, 2011, representing an increase of $225,000, or 5.0%.

The Company reported an operating loss of $(30,000) in the second quarter of 2012, compared to operating income of $175,000 in the second quarter of 2011. Net loss for the second quarter of 2012 was $(77,000), or $(0.00) per share, compared to net income of $123,000, or $0.01 per share in the second quarter of 2011. Operating loss for the first six months of 2012 was $(199,000), compared to an operating loss of $(198,000) in the first six months of 2011. Net loss for the first half of 2012 was $(283,000), or $(0.01) per share, compared to a net loss of $(301,000), or $(0.01) per share in the first half of 2011.

ABMC Chief Executive Officer Stan Cipkowski stated, "We are achieving sales growth in certain markets but, as a US manufacturer, we continue to struggle to be cost-competitive in other markets. I remain confident that our investments in sales and marketing in the first quarter of 2012 and our investments in new product development will enable us to see more positive results later this year and into 2013."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2011, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

(financial tables follow)

AMERICAN BIO MEDICA CORPORATION
Statements of Operations
(unaudited)
For the three For the three For the six For the six
months ended months ended months ended months ended
June 30, 2012 June 30, 2011 June 30, 2012 June 30, 2011
Net sales $ 2,462,000 $ 2,486,000 $ 4,758,000 $ 4,533,000
Cost of goods sold 1,420,000 1,335,000 2,753,000 2,620,000
Gross profit 1,042,000 1,151,000 2,005,000 1,913,000
Operating expenses:
Research and development 55,000 57,000 108,000 109,000
Selling and marketing 529,000 445,000 1050,000 902,000
General and administrative 488,000 474,000 1,046,000 1,100,000
Total operating expenses 1,072,000 976,000 2,204,000 2,111,000
Operating (loss) / income (30,000 ) 175,000 (199,000 ) (198,000 )
Other expense (44,000 ) (51,000 ) (86,000 ) (102,000 )
Net (loss) / income before tax (74,000 ) 124,000 (285,000 ) (300,000 )
Income tax (expense) / benefit (3,000 ) (1,000 ) 2,000 (1,000 )
Net (loss) / income $ (77,000 ) $ 123,000 $ (283,000 ) $ (301,000 )
Basic & diluted (loss) / income per common share
$
(0.00
)
$
0.01
$
(0.01
)
$
(0.01
)
Weighted average shares outstanding - basic
21,744,768
21,744,768
21,744,768
21,744,768
Weighted average shares outstanding - diluted
21,744,768
21,827,564
21,744,768
21,744,768
American Bio Medica Corporation
Balance Sheets
June 30, December 31,
2012
2011
(unaudited)
ASSETS
Current Assets
Cash and cash equivalents $ 15,000 $ 93,000
Accounts receivable, net of allowance for doubtful accounts of $50,000 at June 30, 2012 and $66,000 at December 31, 2011
1,159,000
883,000
Inventory, net of allowance for slow moving and obsolete inventory of $449,000 at June 30, 2012 and $401,000 at December 31, 2011
3,390,000
3,239,000
Prepaid expenses and other current assets 68,000 61,000
Total current assets 4,632,000 4,276,000
Property, plant and equipment, net 1,252,000 1,304,000
Debt issuance costs, net 3,000 26,000
Patents 23,000 0
Other assets 30,000 30,000
Total assets $ 5,940,000 $ 5,636,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable 1,384,000 631,000
Accrued expenses and other current liabilities 139,000 217,000
Wages payable 232,000 264,000
Line of credit 377,000 397,000
Current portion of long-term debt and unearned grant 1,430,000 882,000
Total current liabilities 3,562,000 2,391,000
Other liabilities 144,000 143,000
Long-term debt 0 608,000
Related party note 124,000 124,000
Total liabilities 3,830,000 3,266,000
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity:
Common stock 217,000 217,000
Additional paid-in capital 19,409,000 19,386,000
Accumulated deficit (17,516,000 ) (17,233,000 )
Total stockholders’ equity 2,110,000 2,370,000
Total liabilities and stockholders’ equity $ 5,940,000 $ 5,636,000

Contact:
American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer